Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986 · cited 7×
“Zoledronate [104] NED [104] [104] [104] NED”
BackgroundMethodInfluentialLiberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277 · cited 1×
“Alendronate [17] [163] [17] [135, 164] d [135] [164]”
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003 · cited 2×
“A further trial with once yearly IV zoledronate in patients after hip fracture showed that prevention of further nonvertebral fractures could be significantly reduced [136].”
BackgroundEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maalouf, N., Gottschalk, F. A., & Pak, C. Y. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0952 · Cited by 1,432
Cited by
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., & O'Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,905
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Self-citationOsteoporosis treatment: recent developments and ongoing challenges
Khosla, S., & Hofbauer, L. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30188-2 · Cited by 1,019
Surface Modification Using Phosphonic Acids and Esters
Queffélec, C., Petit, M., Janvier, P., Knight, D. A., & Bujoli, B. (2012) · Chemical Reviews · doi:10.1021/cr2004212 · Cited by 868
Denosumab and bisphosphonates: Different mechanisms of action and effects
Baron, R., Ferrari, S., & Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2010.11.020 · Cited by 715
Self-citationImpact of Dental Implant Surface Modifications on Osseointegration
Smeets, R., Stadlinger, B., Schwarz, F., Beck-Broichsitter, B., Jung, O., Precht, C., Kloss, F., Gröbe, A., Heiland, M., & Ebker, T. (2016) · BioMed Research International · doi:10.1155/2016/6285620 · Cited by 701
Adler, R. A., El-Hajj Fuleihan, G., Bauer, D. C., Camacho, P. M., Clarke, B. L., Clines, G. A., Compston, J. E., Drake, M. T., Edwards, B. J., Favus, M. J., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2708 · Cited by 672
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Miller, P. D., Yang, Y.-C., Grazette, L., San Martin, J., & Gallagher, J. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1502 · Cited by 623
Brown, J. P., Prince, R. L., Deal, C., Recker, R. R., Kiel, D. P., de Gregorio, L. H., Hadji, P., Hofbauer, L. C., Álvaro-Gracia, J. M., Wang, H., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0809010 · Cited by 610
Miller, P. D., Bolognese, M. A., Lewiecki, E. M., McClung, M. R., Ding, B., Austin, M., Liu, Y., & San Martin, J. (2008) · Bone · doi:10.1016/j.bone.2008.04.007 · Cited by 578
Long-Term Use of Bisphosphonates in Osteoporosis
Watts, N. B., & Diab, D. L. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1947 · Cited by 542
Self-citationKendler, D. L., Roux, C., Benhamou, C. L., Brown, J. P., Lillestol, M., Siddhanti, S., Man, H.-S., Martin, J. S., & Bone, H. G. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090716 · Cited by 453
Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday
McClung, M., Harris, S. T., Miller, P. D., Bauer, D. C., Davison, K. S., Dian, L., Hanley, D. A., Kendler, D. L., Yuen, C. K., & Lewiecki, E. M. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.06.023 · Cited by 451
The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data
Allen, M. R., & Burr, D. B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.007 · Cited by 451
The relationship between the chemistry and biological activity of the bisphosphonates
Ebetino, F. H., Hogan, A.-M. L., Sun, S., Tsoumpra, M. K., Duan, X., Triffitt, J. T., Kwaasi, A. A., Dunford, J. E., Barnett, B. L., Oppermann, U., et al. (2011) · Bone · doi:10.1016/j.bone.2011.03.774 · Cited by 391
Self-citationDenosumab: mechanism of action and clinical outcomes
Hanley, D. A., Adachi, J. D., Bell, A., & Brown, V. (2012) · International Journal of Clinical Practice · doi:10.1111/ijcp.12022 · Cited by 377
Adverse Effects of Bisphosphonates: A Comparative Review
Adami, S., & Zamberlan, N. (1996) · Drug Safety · doi:10.2165/00002018-199614030-00003 · Cited by 377
Bone loss in inflammatory disorders
Hardy, R., & Cooper, M. S. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0568 · Cited by 365
Fliefel, R., Tröltzsch, M., Kühnisch, J., Ehrenfeld, M., & Otto, S. (2015) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2015.01.026 · Cited by 363
Bone Morphogenetic Protein-2 in Development and Bone Homeostasis
Halloran, D., Durbano, H. W., & Nohe, A. (2020) · Journal of Developmental Biology · doi:10.3390/jdb8030019 · Cited by 348
Strontium signaling: Molecular mechanisms and therapeutic implications in osteoporosis
Saidak, Z., & Marie, P. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.009 · Cited by 334
Shi, L., Ding, P., Wang, Y., Zhang, Y., Ossipov, D., & Hilborn, J. (2019) · Macromolecular Rapid Communications · doi:10.1002/marc.201800837 · Cited by 303
Extracellular matrix networks in bone remodeling
Alford, A. I., Kozloff, K. M., & Hankenson, K. D. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.05.008 · Cited by 300
Atypical fractures of the femur and bisphosphonate therapy
Giusti, A., Hamdy, N. A. T., & Papapoulos, S. E. (2010) · Bone · doi:10.1016/j.bone.2010.05.019 · Cited by 295
Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis
Costa, A. G., Cusano, N. E., Silva, B. C., Cremers, S., & Bilezikian, J. P. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.77 · Cited by 287
Seeman, E., Delmas, P. D., Hanley, D. A., Sellmeyer, D., Cheung, A. M., Shane, E., Kearns, A., Thomas, T., Boyd, S. K., Boutroy, S., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.81 · Cited by 286
Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability
Bellido, T., & Plotkin, L. I. (2011) · Bone · doi:10.1016/j.bone.2010.08.008 · Cited by 265
Pelegrin, P., & Surprenant, A. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.163 · Cited by 264
Allen, M. R., & Burr, D. B. (2011) · Bone · doi:10.1016/j.bone.2010.10.159 · Cited by 219
COPD, Bone Metabolism, and Osteoporosis
Lehouck, A., Boonen, S., Decramer, M., & Janssens, W. (2011) · Chest · doi:10.1378/chest.10-1427 · Cited by 211
Lin, T.-J., & Heinz, H. (2016) · The Journal of Physical Chemistry C · doi:10.1021/acs.jpcc.5b12504 · Cited by 187
Guañabens, N., Monegal, A., Cerdá, D., Muxí, Á., Gifre, L., Peris, P., & Parés, A. (2013) · Hepatology · doi:10.1002/hep.26466 · Cited by 99
“By contrast, alendronate is a worldwide-approved drug and it is well established for the treatment of osteoporosis.(17) However, its weekly administration has prompted researchers to search a bisphosphonate with less frequent dosing intervals, such as a once-monthly oral regimen.”
Physiology of the aging bone and mechanisms of action of bisphosphonates
Dominguez, L. J., Di Bella, G., Belvedere, M., & Barbagallo, M. (2011) · Biogerontology · doi:10.1007/s10522-011-9344-5 · Cited by 66
“The presence/absence of nitrogen in the side chain divides molecules into those less potent of the first generation (non-N-BPs, i.e., etidronate, clodronate, tiludronate) and those more potent (N-BPs) of the second and third generation with aliphatic alkyl-amino group (i.e., alendronate, ibandronate, pamidronate, neri…”
BackgroundInfluentialSondergaard, B. C., Catala-Lehnen, P., Huebner, A. K., Bay-Jensen, A.-C., Schinke, T., Henriksen, K., Schilling, S., Haberland, M., Nielsen, R. H., Amling, M., et al. (2012) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2011.11.004 · Cited by 38
Alendronate-modified polymeric micelles for the treatment of breast cancer bone metastasis
Liu, T., Romanova, S., Wang, S., Hyun, M. A., Zhang, C., Cohen, S. M., Singh, R. K., & Bronich, T. K. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01343 · Cited by 34
The effect of osteoporosis treatments on fatigue properties of cortical bone tissue
Brock, G. R., Chen, J. T., Ingraffea, A. R., MacLeay, J., Pluhar, G. E., Boskey, A. L., & van der Meulen, M. C. H. (2015) · Bone Reports · doi:10.1016/j.bonr.2014.10.004 · Cited by 33
Osteosarcopenia in NAFLD/MAFLD: an underappreciated clinical problem in chronic liver disease
Musio, A., Perazza, F., Leoni, L., Stefanini, B., Dajti, E., Menozzi, R., Petroni, M. L., Colecchia, A., & Ravaioli, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087517 · Cited by 26
Aspenberg, P. (2013) · BoneKEy Reports · doi:10.1038/bonekey.2012.244 · Cited by 24
“Bisphosphonates adhere to bone and may stay for decades in the skeleton.(19) Still, the bisphosphonateassociated risk diminishes rapidly after cessation of bisphosphonate use.”
BackgroundBisphosphonate-incorporated coatings for orthopedic implants functionalization
Zhang, J., Bai, H., Bai, M., Wang, X., Li, Z., Xue, H., Wang, J., Cui, Y., Wang, H., Wang, Y., et al. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100737 · Cited by 22
“[104] indicated that ALN, ZOL, and ibandronate could induce a more positive zeta potential on the HA surface at PH 7.”
BackgroundBakr, M. M., Kelly, W. L., Brunt, A. R., Paterson, B. C., Massa, H. M., Morrison, N. A., & Forwood, M. R. (2020) · JBMR Plus · doi:10.1002/jbm4.10387 · Cited by 4
“BPs are known to have a long residence time in bone, and to also be recycled and return to other resorptive surfaces even after the treatment has ceased.((3,65)) Limited data are available from BP discontinuation clinical trials, but suggest a residual and continuous biological effect of BPs, especially ALN and zoledr…”
BackgroundSambrook, P. N., Roux, C., Devogelaer, J.-P., Saag, K., Lau, C.-S., Reginster, J.-Y., Bucci-Rechtweg, C., Su, G., & Reid, D. M. (2012) · Bone · doi:10.1016/j.bone.2011.10.024 · Cited by 3
“Since bone turnover differs by gender and age and the effects of glucocorticoids on sex steroid production also differ between the sexes [17,34], it is important to examine how agents such as bisphosphonates, which have been reported to be effective in several trials for the prevention and treatment of GIO [21,22,24,2…”
BackgroundInfluential
Metadata
- Authors
- Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J.
- Venue
- Osteoporosis International
- Published
- 2008-01-24
- Volume
- 19
- Issue
- 6
- Pages
- 733-759
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2134304734
- Cited by
- 1,411
- References
- 144
- FWCI
- 41.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.